https://doi.org/10.1186/ar3257
X
Xinjun Liang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
88
Papers
1.0K
Citations
15
h-index
28
i10-index
Xinjun Liang is an academic researcher from Shanxi Medical University. The author has contributed to research in topics: Monoclonal and Polyclonal Antibodies Research & HER2/EGFR in Cancer Research & Radiopharmaceutical Chemistry and Applications. The author has an h-index of 15, co-authored 75 publications.
ORCID: 0000-0002-5180-7926Papers by this author
worksRETRACTED ARTICLE: Reduced immunomodulation potential of bone marrow-derived mesenchymal stem cells induced CCR4+CCR6+Th/Treg cell subset imbalance in ankylosing spondylitis
2011 · Arthritis Research & Therapy · 84 citations
A Low Advanced Lung Cancer Inflammation Index Predicts a Poor Prognosis in Patients With Metastatic Non–Small Cell Lung Cancer
2022 · Frontiers in Molecular Biosciences · 15 citations
https://doi.org/10.3389/fmolb.2021.784667
Creation of a Novel Nomogram Based on the Direct Bilirubin-To-Indirect Bilirubin Ratio and Lactate Dehydrogenase Levels in Resectable Colorectal Cancer
2021 · Frontiers in Molecular Biosciences · 12 citations
https://doi.org/10.3389/fmolb.2021.751506
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Clinical Cancer Research · 10 citations
https://doi.org/10.1158/1078-0432.ccr-24-4280
1707MO A phase II dose expansion study of ZG006, a trispecific T cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with refractory neuroendocrine carcinoma
2025 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2025.08.2335
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat